English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The progesterone vaginal ring (PVR) is a contraceptive designed specifically for use by breastfeeding women in the first year postpartum. The PVR is inserted in the vagina 30-90 days postpartum for continuous use for up to 3 months and replaced with a new ring if breastfeeding is continued and extended contraception is desired. Women can use four rings successively for up to one year. The progesterone vaginal ring functions by diffusing a continuous flow of progesterone through the vaginal walls--approximately 10 mg per day--which then enters the bloodstream and regulates the woman’s fertility by suppressing ovulation. Clinical trials have proven the PVR to be a safe and effective contraceptive; furthermore it is currently registered in eight countries in Latin America. The PVR has also been included in the 2015 WHO Essential Medicines List and the Medical Eligibility Criteria guidance. This study was part of a series of activities that assess the feasibility of and preparation for introduction of the PVR into Kenya Nigeria and Senegal. (excerpt)

Progesterone vaginal ring: Results of a three-country acceptability study